Goldman Sachs has reinstated its analysis of Ideaya Biosciences, assigning a Neutral rating to the stock with a price target of $25. The financial firm anticipates that 2025 will be a critical year for Ideaya Biosciences as the company is expected to focus on executing its strategic plans. Investors will be watching closely to see how these plans unfold in the coming years, as the company's progress could significantly impact its market position and stock performance.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 11 analysts, the average target price for IDEAYA Biosciences Inc (IDYA, Financial) is $46.27 with a high estimate of $58.00 and a low estimate of $27.00. The average target implies an upside of 101.45% from the current price of $22.97. More detailed estimate data can be found on the IDEAYA Biosciences Inc (IDYA) Forecast page.
Based on the consensus recommendation from 14 brokerage firms, IDEAYA Biosciences Inc's (IDYA, Financial) average brokerage recommendation is currently 1.6, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for IDEAYA Biosciences Inc (IDYA, Financial) in one year is $20.02, suggesting a downside of 12.84% from the current price of $22.97. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the IDEAYA Biosciences Inc (IDYA) Summary page.
